Liverpool manager hopes signings will provide fresh hunger but he needs strong backroom personalities around him, too

On the opening weekend last season, Liverpool went to Fulham and, after twice falling behind, drew 2-2. Coming a week after the Community Shield win over Manchester City, the positive impression of Darwin Núñez seemed to be confirmed but the broader feeling was of doubt. Liverpool just didn’t look at it. They didn’t overwhelm Fulham physically as they had so many teams previously. Fabinho looked off the pace. Virgil van Dijk, such a commanding figure before then, was given a chasing by Aleksandar Mitrovic. Further doubts were raised about Trent Alexander‑Arnold’s defending.

Early-season observations can be made to look very silly very quickly. Núñez did not, last season, develop into the imposing and prolific presence it appeared he might. But that other impression remained valid. Liverpool had lost their physical advantage. The question was why? Was it a short-term issue related, perhaps, to a dulling of appetite having come so close to a quadruple the previous season or to their ageing midfield? Had something gone slightly awry with their press, as had happened during the Covid-affected season of 2020-21? Or was it something more profound? Had other teams caught up with Liverpool in terms of physical preparation?

Continue reading…

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Youngest pupils in England worst affected by Covid learning loss

Data finds those aged six and seven most likely to fall behind…

Volodymyr Zelenskiy publishes collection of war speeches as ‘battle cry for the world’

A Message from Ukraine includes 16 speeches selected by the president as…

Grant Shapps resists blanket border controls to stem Covid in Britain

Minister tells MPs practicalities rule out island nation copying Australia, as Hancock…

Rishi Sunak refuses to say if he will profit from Moderna Covid vaccine

Chancellor’s former hedge fund invested heavily in Moderna, which had 94.5% trial…